34th International Epilepsy Congress

16:30-17:30 CEST

LivaNova: Beyond Seizures: A systematic approach towards identifying and managing epilepsy’s most burdensome comorbidities

Chair: Maxine Dibué (Germany)

- Cardiac complications in epilepsy: when to expect, what to do? - Rainer Surges (Germany)

- Sleep and epilepsy: interactions and implications  - Berthold Voges (Germany)

- Why do we need to assess cognition in patients with epilepsy?  - Jukka Peltola (Finland)

- Managing comorbid depression in epilepsy - Tim von Oertzen (Austria)

17:00-18:00 CEST

GW Pharmaceuticals: Management of multiple seizure types in rare and severe early-onset epilepsies

Chair: Lieven Lagae (Belgium)

- Challenges and barriers in the management of patients with multiple seizure types - Ailsa McLellan (United Kingdom)

- Current options in the treatment of rare epilepsies - Lieven Lagae (Belgium)

- Broad spectrum antiseizure effects of GW cannabidiol in LGS, DS and TSC - Hari Bhathal (Spain)

- Q&A

20:00-21:00 CEST

Miller Medical Communications, LLC. (Zogenix supported): A New Look at the Natural Course of Dravet Syndrome: Can We Influence It?

Chair: Andreas Brunklaus (United Kingdom)

- The Importance of Understanding the Natural Course of Dravet Syndrome - Andreas Brunklaus (United Kingdom)

- Dravet Syndrome Stage 1 - Andreas Brunklaus (United Kingdom)

- Dravet Syndrome Stage 2 - Joseph Sullivan (USA)

- Dravet Syndrome Stage 3 - Adam Strzelczyk (Germany)

- Q&A

09:00-10:00 CEST

UCB: The future of the epilepsies: innovation, transformation and evolution

Chair: Marte Syvertsen (Norway)

- Helpilepsy – Utilising remote monitoring of epilepsy to improve patient outcomes via actionable insights - Jonathan Schreiber(Belgium)

- Healios – Considering an emotional wellbeing and mental health app as part of the epilepsy treatment pathway - Richard Andrews (United Kingdom)

- Neuro Event Labs – Using computer vision and machine learning to support diagnosis and monitoring of epilepsy patients - Kaapo Annala (Finland)

- How is UCB utilising experience and expertise to develop new differentiated medicines, with the aim of improving the lives of patients living with epilepsy? - Stefanie Dedeurwaerdere (Belgium)

12:00-13:00 CEST

(repeat) GW Pharmaceuticals: Management of multiple seizure types in rare and severe early-onset epilepsies

Chair: Lieven Lagae (Belgium)

- Challenges and barriers in the management of patients with multiple seizure types - Ailsa McLellan (United Kingdom)

- Current options in the treatment of rare epilepsies - Lieven Lagae (Belgium)

- Broad spectrum antiseizure effects of GW cannabidiol in LGS, DS and TSC - Hari Bhathal (Spain)

- Q&A

17:00-18:00 CEST

UCB: Bridging the gap: what do patients want from the management of their epilepsy?

Chair: Christian Brandt (Germany)

- Introduction and discussion of the latest patient preference data - Christian Brandt (Germany)

- Efficacy vs tolerability: do you need to compromise?  - Philippe Ryvlin (Switzerland)

- Efficacy vs tolerability: do you need to compromise? - Vasilios Kimiskidis (Greece)

20:00-21:00 CEST

BioMarin: Looking beyond the seizure: Why early diagnosis for paediatric epilepsy matters

Chair: Nicola Specchio (Italy)

- Differential diagnosis of early-onset paediatric epilepsies - Nicola Specchio (Italy)

- Why reducing diagnostic delay matters in practice - Ingrid Scheffer (Australia)

- Interactive Live Discussion

09:00-10:00 CEST

Eisai: Harnessing real-world data to improve outcomes in people with epilepsy

Chair: Emilio Perucca (Italy)

- Real-world studies in epilepsy: benefits and limitations - Nuno Canas (Portugal)

- Evidence from clinical practice studies – the best insight into antiseizure medications? - Vicente Villanueva (Spain)

11:30-12:30 CEST

(repeat) UCB: Bridging the gap: what do patients want from the management of their epilepsy?

Chair: Christian Brandt (Germany)

- Introduction and discussion of the latest patient preference data - Christian Brandt (Germany)

- Efficacy vs tolerability: do you need to compromise?  - Philippe Ryvlin (Switzerland)

- Efficacy vs tolerability: do you need to compromise? - Vasilios Kimiskidis (Greece)

17:00-18:00 CEST

Arvelle Therapeutics – An Angelini Pharma Company: Aiming for seizure freedom: a patient-centric approach to drug-resistant epilepsy

Chair: Emilio Perucca (Italy)

- A life without limits: why we should strive for seizure freedom for our patients - Jacqueline French (USA)

- Current challenges and unmet needs in adults with drug-resistant focal onset seizures - Ley Sander (United Kingdom)

- Redefining patient outcomes in drug-resistant focal onset seizures: clinical experience with novel therapies - Bernhard Steinhoff (Germany)

09:00-10:00 CEST

PTC Therapeutics: A practical approach – epilepsy misdiagnosis in clinical practice

Chair: Agathe Roubertie (France)

- Unmasking differential diagnosis of epilepsy – a focus on AADC deficiency - Agathe Roubertie (France)

- AADC deficiency diagnosis: How to recognise the red flags in clinical practice – a case study - Regina Trollmann (Germany)

- The key role of carers in AADC deficiency: The importance of early diagnosis - Richard Poulin (Singapore)

11:00-12:00 CEST

(repeat) BioMarin: Looking beyond the seizure: Why early diagnosis for paediatric epilepsy matters

Chair: Nicola Specchio (Italy)

- Differential diagnosis of early-onset paediatric epilepsies - Nicola Specchio (Italy)

- Why reducing diagnostic delay matters in practice - Ingrid Scheffer (Australia)

- Interactive Live Discussion

13:00-14:00 CEST

(repeat) Arvelle Therapeutics – An Angelini Pharma Company: Aiming for seizure freedom: a patient-centric approach to drug-resistant epilepsy

Chair: Emilio Perucca (Italy)

- A life without limits: why we should strive for seizure freedom for our patients - Jacqueline French (USA)

- Current challenges and unmet needs in adults with drug-resistant focal onset seizures - Ley Sander (United Kingdom)

- Redefining patient outcomes in drug-resistant focal onset seizures: clinical experience with novel therapies - Bernhard Steinhoff (Germany)

14:30-14:50 CEST

GW Pharmaceuticals: Best practice in management of patients on cannabidiol: Expert clinical cases

- Angela Kaindl (Germany)

- Elizabeth Thiele (USA)

12:00-12:20 CEST

Arvelle Therapeutics – An Angelini Pharma Company: Clinical experience with cenobamate

-  Gregory Krauss (USA)